compound
PT-141 (10mg Vial) Questions Answered
PT‑141 (bremelanotide) is a melanocortin receptor agonist that acts centrally—predominantly via MC4R—to influence sexual desire pathways [7] [8] .
PT-141 (10mg Vial)
Route: Subcutaneous (abdomen or thigh). Frequency: PRN only — 1 dose ≥45 minutes before activity; max 1/24 h and ≤8/month[1]. Volume tolerance: SC injections of up to ~3.0 mL are generally well‑tolerated in the abdomen[5][6].
PT‑141 (bremelanotide) is a melanocortin receptor agonist that acts centrally—predominantly via MC4R—to influence sexual desire pathways [7] [8] .
Route: Subcutaneous (abdomen or thigh). Frequency: PRN only — 1 dose ≥45 minutes before activity; max 1/24 h and ≤8/month[1]. Volume tolerance: SC injections of up to ~3.0 mL are generally well‑tolerated in the abdomen[5][6].
Plan based on PRN use (≤8 doses/month) with a 1.75 mg standard dose [1] . At this dilution, each 10 mg vial provides 5 full doses (0.525 mL per dose × 5 = 2.625 mL used; a sixth would exceed 3.0 mL).
Practical considerations for consistent technique and safety. Use new sterile insulin syringes and dispose of sharps appropriately; follow aseptic preparation [3] .